Today, Vertex released positive preliminary clinical trial results for the potential triple-combination therapy VX-445 plus tezacaftor/ivacaftor (Symdeko®).
Site Search
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.
The Cystic Fibrosis Foundation has entered into an agreement with Synspira Therapeutics Inc. to develop a non-porcine enzyme replacement therapy to offer an alternative to people with cystic fibrosis who cannot digest food properly.
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.
Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.
Cystic Fibrosis Foundation Therapeutics Inc. has awarded more than $4 million to AlgiPharma AS to continue Phase 2 clinical trials for a drug that may help restore normal function to cystic fibrosis mucus and make it easier for people with CF to cough out.
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.
Leaders of the Cystic Fibrosis Foundation and dedicated volunteers from the CF community came together last week around a shared commitment to not stop working until a cure is found for every person living with cystic fibrosis.
Phase 2 clinical trial results were announced today for a potential next-generation modulator to treat people with two copies of the most common cystic fibrosis mutation, F508del.